drugset
drugset / Trial / NCT05399030

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

NCT05399030 ↗

Phase 1 Completed 72 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
RandomizedSequentialTriple-blindOther

Summary

This is a randomized, double-blind, placebo-controlled, parallel group, single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in Healthy Subjects

Timeline

Start
2021-08-14
Primary completion
2022-01-30
Completion
2022-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ICP-332 Unknown — —

Indications

No indication recorded.